Background: The transcription factor signal transducer and activator of transcription 3 (STAT3) is implicated in cancer drug resistance, metastasis, and immunosuppression and has been identified as a promising therapeutic target for new anticancer drugs.
| INTRODUCTION
Prostate cancer is the second most common cancer in men according to the World Health Organization, with 1.1 million newly diagnosed men and 307 000 reported deaths worldwide in 2012. 1 Novel therapeutic agents for treatment of advanced and metastatic castration-resistant prostate cancer (mCRPC) include cabazitaxel, abiraterone acetate, enzalutamide, and radium-223, which all have shown survival benefits.
However, most patients become treatment-resistant within a few years. 2, 3 Furthermore, immunotherapies have shown little efficacy in prostate cancer until today. 4 There is an urgent need to develop novel therapies for treatment-resistant prostate cancer.
Cancer cells may avoid the immune defense by inhibiting immune responses or by activating immunosuppressive mechanisms, creating a favorable tumor microenvironment that leads to cancer cell survival, growth, and metastatic spread. The transcription factor Signal Transducer and Activator of Transcription 3 (STAT3) is implicated in acquired drug resistance, metastasis, and immune suppression and has been identified as a relevant and promising target for the development of new drugs against cancer. [5] [6] [7] The STAT3 signaling pathway is highly involved in the interaction between cancer cells and the tumor microenvironment, particularly in the inhibition of immune responses and induction of immunosuppressive cells, thus promoting immune evasion. 8, 9 Myeloid-derived suppressor cells (MDSCs) are known to play a major role in the suppression of antitumor immunity and STAT3 signaling is involved in the accumulation, generation, and ultimately, functioning of MDSCs. 5, 8, 10 Elevated levels of MDSCs have been found in the peripheral blood and in tumor tissue of prostate cancer patients, and the levels correlate with disease progression. [11] [12] [13] [14] [15] MDSCs are immature myeloid cells with potent immunosuppressive functions in the tumor microenvir-
onment. MDSCs act by inhibiting T cells through various mechanisms
including an increased arginase-1 activity causing L-arginine depletion, expression of inducible nitric oxide synthase leading to increased levels of reactive oxygen species and nitric oxide, and by elevated levels of indoleamine 2,3-dioxigenase (IDO) causing a reduction in local tryptophan levels. Furthermore, MDSCs secrete the immunosuppressive factors IL10 and transforming growth factor β. STAT3 has been shown to regulate the expression of both the immunosuppressive proteins IDO and arginase-1 and the secretion of tumor promoting and immunosuppressive factors eg, IL6, IL10, and vascular endothelial growth factor (VEGF) 9, 16, 17 thus making STAT3 a relevant target for alleviating immunosuppression.
MDSCs have been identified as targets for cancer therapy and to improve immunotherapy and in this context targeting STAT3 in MDSCs is suggested to be a promising therapeutic approach. 5, [18] [19] [20] Inhibiting STAT3 in MDSCs isolated from patients with prostate cancer using STAT3 small interfering RNA resulted in MDSCs with decreased immunosuppressive activity 12 and the tyrosine kinase inhibitor sunitinib was shown to inhibit STAT3 in MDSCs and to reduce MDSC levels in renal cell carcinoma. 21 Galiellalactone is a STAT3 inhibitor exerting its effect through inhibition of the expression of STAT3 regulated genes by directly binding to STAT3, thus blocking the protein-DNA interaction. 22, 23 Galiellalactone inhibits the proliferation of prostate cancer cells expressing active phosphorylated STAT3 (pSTAT3) and induces apoptosis by downregulation of STAT3-activated genes. 23 In previous studies, we have demonstrated that galiellalactone inhibits tumor growth and metastatic spread in an orthotopic prostate cancer mouse model. 24 There are limited treatment options for metastatic treatmentresistant prostate cancer patients and existing immunotherapies have shown little efficacy in prostate cancer. 4 However, targeting the immunosuppressive environment in prostate cancer may improve treatment outcomes. Thus, inhibition of STAT3 in this disease setting emerges as a very interesting therapeutic approach.
In this study, we aimed to investigate whether the STAT3 inhibitor galiellalactone could block the generation of cells with an MDSC-like phenotype derived from primary human monocytes, in the presence of prostate cancer cells, ex vivo. We also investigated the effect of galiellalactone on immunosuppressive factors in the generated MDSClike monocytes and the secretion of inflammatory cytokines and tumorigenic factors from both prostate cancer cells and monocytes.
| MATERIALS AND METHODS

| Isolation of peripheral blood monocytes from metastatic prostate cancer patients and MDSC analysis
Peripheral blood was collected in EDTA tubes from patients with mCRPC (n = 9) and analyzed within 24 hours. Peripheral blood mononuclear cells (PBMCs) were enriched by density gradient centrifugation using Ficoll-Paque Plus (Amersham Biosciences). Permission was obtained from the Regional Ethical Review Board in Lund (Dnr 2013/400). PBMCs were analyzed for monocytic MDSCs (CD11b + CD14 + HLA-DR −/lo ) using flow cytometry analysis as described below. CD14 + HLDR −/lo cells were isolated from PBMCs from patients with mCRPC using BD FACSAria Cell Sorter and subjected to cytospin and analyzed for pSTAT3 expression as described below.
| Isolation of monocytes from healthy donors
PBMCs were isolated from healthy donors by density gradient centrifugation using Ficoll-Paque Plus (Amersham Biosciences).
Permission was obtained from the Regional Ethical Review Board in Lund (Dnr 2017/949). Monocytes were isolated from PBMCs by magnetic sorting using Monocyte Isolation Kit II (Miltenyl Biotec). Monocytes were also cultured with CM from prostate cancer cells without the presence of prostate cancer cells. Monocytes were cultured with or without galiellalactone for 72 hours before further analysis. Galiellalactone was provided by Glactone Pharma AB (Helsingborg, Sweden).
| Flow cytometry analysis
| Cytometric bead array for human inflammatory cytokines
Monocytes and prostate cancer cells were cultured with or without the presence of galiellalactone for the indicated time points. Cytokine secretion was evaluated in supernatants of prostate cancer cell cultures and monocyte cultures using Cytometric Bead Array Human Inflammatory Cytokines (BD Bioscience) according to the manufacturerʼs instructions.
The cytokines IL8, IL1β, IL6, tumor necrosis factor (TNF), IL10, and IL12p70 were analyzed. The levels of cytokines were evaluated using CytoFLEX from Beckman Coulter Inc with subsequent analysis using FlowJo software.
| Cytospin and immunocytochemistry
Suspensions of monocytes cultured for 72 hours in CM from prostate cancer cells or MDSCs isolated from mCRPC patients were placed in a cytospin funnel clamped to a glass slide and spun at 800 rpm for 2 minutes. The slides were air-dried, fixed in 4% formaldehyde for 10 minutes, and permeabilized with 1% Triton-X Tris buffer, pH 7.6 for 1 hour. The slides were subjected to immunohistochemistry using Dako Autostainer Plus En Vision TM + Kit (Dako). Cells were stained using the antibody anti-pSTAT3
Tyr-705 (ab76315; Abcam).
| Western blot
Prostate cancer cell lysates were prepared and analyzed by Western blot analysis as in a previous publication. 22 Primary antibodies used were anti-STAT3 (#4904; Cell Signaling Technology), anti-pSTAT3 Tyr-705 (ab76315; Abcam) and anti-beta-actin (#691001;
BioMedicals MP) was used as loading control.
| Quantitative real-time polymerase chain reaction
The gene expression of IL6, IL8, VEGF, granulocyte macrophagecolony stimulating factor (GM-CSF), IL23, arginase-1, and IDO was from PBMCs from healthy donors were cultured in vitro in the presence of CM from prostate cancer cells or cocultured together with prostate cancer cells in a transwell system for 72 hours (Figure 2A and   2B ). Monocytes cocultured with DU145, LNCaP-IL6, and PC3 cells or in the presence of CM from DU145 and LNCaP-IL6 cells showed an increased population of CD14 + HLA-DR −/lo cells compared to control monocytes (Figure 2A ). The increase in CD14 + HLA-DR −/lo population was most pronounced in monocytes cultured with DU145 cells or DU145 CM (Figure 2A and 2B) . 
| STAT3 inhibition by galiellalactone prevents prostate cancer cell-induced generation of MDSC-like monocytes
| Galiellalactone decreases IL8 and GM-CSF in prostate cancer cells
A panel of secreted cytokines (IL8, IL1β, IL6, TNF, IL10, and IL12p70) was investigated in the CM of prostate cancer cells after 48 hours of culture. High levels of IL6 and IL8 were observed in CM from DU145 and PC3 cells and low levels of IL6 and IL8 in LNCaP-IL6 cells ( Figure   3A and 3B). TNF, IL12p70, IL1β, or IL10 were not detected in CM of the studied prostate cancer cells. Next, we investigated the effect of STAT3 inhibition by galiellalactone on cytokine secretion and expression in DU145 and LNCaP-IL6 cells after 24 hours of culture.
Galiellalactone significantly reduced the levels of secreted IL8 from DU145 and LNCaP-IL6 cells and decreased the IL8 mRNA levels in DU145 cells ( Figure 3C ). Galiellalactone had no significant effect on IL6 secretion or IL6 mRNA expression in DU145 or LNCaP-IL6 cells.
( Figure 3D ). The already low levels of IL6 in LNCaP-IL6 cells were not affected by galiellalactone. Galiellalactone did not alter the levels of TNF, IL12p70, IL1β, or IL10 in the supernatant of prostate cancer cells (data not shown). DU145 cells expressed high levels of GM-CSF mRNA compared with LNCaP-IL6 and PC3 cells, and galiellalactone significantly inhibited GM-CSF mRNA expression in DU145 cells ( Figure 3E ). VEGF mRNA was expressed in DU145 and LNCaP-IL6 cells and at a lower level in PC3 cells ( Figure 3F ). The VEGF expression was not affected by galiellalactone.
| Inflammatory cytokine secretion in monocyte cultures and the effect of galiellalactone
Next, we investigated the levels of inflammatory cytokines secreted by monocytes and the effect on cytokine secretion by factors present in prostate cancer cell CM and the presence of galiellalactone. The levels of IL8, IL1β, IL6, TNF, IL10, and IL12p70 proteins were measured by cytometric bead array in supernatants from monocyte cultures (Figure 4 ). IL6 and IL8 were detected in the supernatant of monocytes as well as low levels of IL1β and IL10. TNF and IL12p70 were not detected. In the presence of prostate cancer cell CM, a significant increase in IL1β and IL10 levels in monocytes was observed ( Figure 4A and 4D). Galiellalactone significantly inhibited the prostate cancer CM-induced increase in IL1β secretion and significantly reduced the levels of IL10 in monocytes ( Figure 4A and 4D ). IL1β and IL10 were not detected in CM from prostate cancer cells indicating that the secretion of these cytokines by monocytes was induced by prostate cancer CM ( Figure 3A ). IL6 levels in monocyte supernatant were significantly increased by DU145 and PC3 CM which was inhibited in the presence of galiellalactone. There was no effect of galiellalactone on the levels of IL8 in the supernatant of monocytes ( Figure 4C ).
| Expression of the immunosuppressive markers arginase-1, IDO, IL6, and IL23 in monocytes
We next investigated the expression of markers in monocytes involved in immunosuppressive functions of MDSCs ( Figure 5 ). The mRNA expression of IDO, arginase-1, IL6, and IL23 was investigated in monocytes cultured with prostate cancer cell CM in the presence and absence of galiellalactone ( Figure 5A and 5D ). IDO gene expression in monocytes was decreased by galiellalactone, both in control monocytes and monocytes cultured with prostate cancer CM ( Figure 5A ). Monocytes cultured in the presence of prostate cancer cell CM showed increased IL6 mRNA levels, which was inhibited upon treatment with galiellalactone ( Figure 5B ), which is in accordance with the observed IL6 protein levels in monocyte supernatants ( Figure 4B ). Levels of arginase-1 mRNA in monocytes were unaffected by prostate cancer CM or galiellalactone ( Figure 5C ). IL23 mRNA expression in monocytes was not significantly affected by prostate cancer cell CM or the presence of galiellalactone ( Figure 5D ). C, Effect of galiellalactone on viability of isolated monocytes. Isolated monocytes were cultured with and without galiellalactone for 72 hours. Dead cells were identified by 7-AAD staining and FACS analysis. There was no observed decrease in viability by galiellalactone treatment on monocytes (n = 6). D, Immunohistochemistry for pSTAT3 was performed on monocytes subjected to cytospin. Monocytes cultured with CM from prostate cancer cells for 72 hours showed an increased expression of pSTAT3 compared to monocytes cultured in control medium. E, Western blot analysis for the expression of pSTAT3 and STAT3 cell in lysates from the prostate cancer cells PC3, DU145, and LNCaP-IL6. β-Actin is used as a loading control. MDSC, myeloid-derived suppressor cell; pSTAT3, phosphorylated STAT3; STAT3, signal transducer and activator of transcription 3 [Color figure can be viewed at wileyonlinelibrary.com] ex vivo and to decrease levels of immunosuppressive and tumorigenic factors in both monocytic MDSCs and cancer cells. We observed an increased level of CD14 + HLA-DR −/lo monocytic MDSCs in the peripheral blood of mCRPC patients compared to healthy controls, which is in line with previous studies in advanced prostate cancer. [13] [14] [15] The isolated monocytic MDSCs from mCRPC patients expressed pSTAT3 in accordance with observations made in various cancers. 16, 26, 27 These results spurred us to investigate the effect of the STAT3 inhibitor galiellalactone on the generation of MDSCs from monocytes by prostate cancer cells ex vivo.
| DISCUSSION
In this study, prostate cancer cells or CM from prostate cancer cells promoted the generation of CD14 + HLA-DR −/lo MDSC-like monocytes from primary human monocytes in culture, and CM from prostate cancer cells increased the expression of pSTAT3 in monocytes. These findings are in line with previous studies, where increased expression of pSTAT3 in monocytes induced by cancer cells ex vivo was associated with MDSC generation. 26, 28 In addition, we could show that markers related to MDSC immunosuppressive function such as IL6 and IL10 were increased in monocytes by F I G U R E 3 Galiellalactone inhibits IL8 and GM-CSF expression in prostate cancer cells. A, Cytokine secretion in conditioned medium (CM) from prostate cancer cells was analyzed using cytometric bead array (CBA). B, IL6 and IL8 protein levels in CM from LNCaP-IL6, DU145, and PC3 cells after 48 hours in culture as measured by CBA (n = 4). C,D, IL6 and IL8 protein levels in cell culture medium relative untreated control cells (n = 3) and IL6 and IL8 mRNA levels (n = 5) in DU145 and LNCaP-IL6 cells after treatment with galiellalactone (GL) at 5 and 10 μM for 24 hours (n = 4). E, GM-CSF mRNA expression levels in prostate cancer cells (n = 2) and the effect of GL on the gene expression of GM-CSF in DU145 cells after 24 hours (n = 4-5). F, VEGF mRNA expression levels in prostate cancer cells (n = 2) and the effect of GL on the gene expression of VEGF in DU145 and LNCaP-IL6 cells after 24 hours (n = 4-5). Data are presented as mean ± SEM. GM-CSF, granulocyte macrophage-colony stimulating factor; IL, interleukin; mRNA, messenger RNA; VEGF, vascular endothelial growth factor [Color figure can be viewed at wileyonlinelibrary.com] galiellalactone treatment further suggests that the effects of STAT3 inhibition on MDSC generation are on the monocytes. However, galiellalactone may also directly act on prostate cancer cells to affect prostate cancer cell-derived factors involved in MDSC generation such as GM-CSF, which was significantly decreased by galiellalactone in DU145 cells. A small increase in CD14 + HLA-DR −/lo monocytes was observed by galiellalactone in monocytes but this was however not accompanied by increased MDSC-related functional markers or cytokines indicating that an immunosuppressive phenotype of monocytes was not induced by galiellalactone.
Factors derived from tumor cells promoting MDSC generation include IL6, IL1β, IL10, GM-CSF, granulocyte colony-stimulating factor and VEGF, 10 all known to activate STAT3 that is a central signaling pathway for generation and function of MDSCs. 8, 19 Many cytokines induced by STAT3 e. g. IL6, IL10, and VEGF also function as STAT3 activators. 9 The prostate cancer cells in this study were shown to secrete IL6, GM-CSF, and VEGF factors likely involved in the observed generation of MDSC-like monocytes although additional factors not investigated may also be involved. The ability to generate MDSC-like monocytes by the different prostate cancer cell lines varied, likely reflecting the different levels and mediators produced by the cancer cells. GM-CSF is one of the most important factors for generation and survival of MDSCs and tumor derived GM-CSF has even been suggested to be responsible for the increased level of MDSCs detected in patients with cancer. 29 In addition to GM-CSF, IL6 is considered an important inducer of MDSCs. 29 Increased levels of GM-CSF and IL6 are observed in metastatic prostate cancer. 30, 31 Galiellalactone had limited effect on prostate cancer cell-derived IL6 and VEGF, factors involved in MDSC generation, although GM-CSF was significantly inhibited. Together this indicates that GM-CSF is the principal effector molecule produced by prostate cancer that is capable of promoting MDSC generation, and that is inhibited by the novel STAT3 inhibitor galiellalactone. indicating that IL6 expression in DU145 cells may be regulated by other transcription factors than STAT3, such as nuclear factor kappalight-chain-enhancer of activated B cells. 37, 38 Galiellalactone inhibited IDO expression in monocytes, suggesting that galiellalactone may prevent immunosuppressive activities. It has previously been shown that IDO is upregulated by IL6 and GM-CSF in MDSCs via activation of STAT3 and that STAT3 inhibition decreased this immunosuppressive activity of MDSCs. 17, 34, 39 Arginase-1 expression and activity in monocytes and MDSCs varies considerably between F I G U R E 5 Expression of arginase-1, IDO, IL6, and IL23 in monocytes. A-D, The mRNA expression of IDO, arginase-1, IL6, and IL23 in monocytes cultured with prostate cancer cell conditioned medium (CM), with or without galiellalactone (GL) for 72 hours. The gene expression levels are presented as relative control monocytes. n = 3-5. Data are presented as mean ± SEM. IDO, indoleamine 2,3-dioxigenase; IL, interleukin; mRNA, messenger RNA individuals, 40 which may explain why we did not find a consistent effect on arginase-1 expression in this study. IL23 secreted by granulocytic MDSCs is observed to be involved in CRPC. 41 However, in this study, we focus on monocytic MDSCs and we did not observe a significant increase in IL23 expression in the monocytic MDSCs generated by prostate cancer cell CM. We observed decreased IL8 secretion by galiellalactone in prostate cancer cells. In prostate cancer patients, increased levels of IL8 are observed in the circulation and correlates with aggressiveness and levels of circulating granulocytic MDSCs. 11 IL8 is a potent angiogenic factor and also functions as a chemoattractant of neutrophils and monocytes, 42 thus inhibition of IL8 secretion in prostate cancer cells may inhibit chemoattractant properties and angiogenic effects in the prostate tumor environment.
To date, there are no approved direct STAT3 inhibitors used in the clinical setting. Clinical trials with the small molecule STAT3 inhibitor Napabucasin, also known as BB1608 or BB608, has shown some efficacy in colorectal cancer. 43 Furthermore, attempts to target STAT3 have been made using the STAT3 antisense oligonucleotide AZD9150 in lymphoma with moderate effect 44 and clinical trials are ongoing for additional malignancies (www.clinicaltrials.gov). As for STAT3 inhibition in prostate cancer, attempts have been made to target IL6 signaling by IL6 monoclonal antibody (Siltuximab) and although preclinical studies show positive results, so far limited antitumoral effects have been observed in clinical trials with prostate cancer patients. 45, 46 We have previously shown that galiellalactone inhibits metastatic spread and growth of pSTAT3 expressing prostate cancer cells, both in vivo and in vitro 23, 24 indicating that STAT3 inhibition by galiellalactone may target both the tumor suppressive environment and tumor cells directly in prostate cancer. In this study, we have shown that STAT3 inhibition by galiellalactone also may target the myeloid cell compartment of tumors thus interrupting important immunosuppressive and tumorpromoting factors derived from both monocytes and prostate cancer cells and inhibit the generation of MDSC-like monocytes.
| CONCLUSION
The STAT3 inhibitor galiellalactone may reverse the immunosuppressive mechanisms caused by the interplay between prostate cancer cells and MDSCs. The results indicate that galiellalactone has powerful effects on immune cells affecting cancer growth and metastasis, further emphasizing that STAT3 inhibitors represent a potential new treatment for advanced prostate cancer.
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